Try
BOSTON SCIENTIFIC CORP
BSXUnited States
65 filed reports · 841 financial concepts · 30 earnings calls · 3 media appearances
Filed reports
65 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 344 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 8,724 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 23 | 184 | Dec 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 8,585 | Dec 2016 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 3, 2026 | 503 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 29, 2026 | 8 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 1, 2026 | 343 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 22, 2026 | 8 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 17, 2026 | 1,388 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 4, 2026 | 8 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 3, 2025 | 428 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 22, 2025 | 8 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 1, 2025 | 266 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 23, 2025 | 8 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 271 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 23, 2025 | 8 | Open |
Financial data
841 concepts · 17,494 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial807 concepts · 13,932 facts · Mar 2014 to Jul 2026
- Fair Value, Inputs, Level 172 · Dec 2018 to Jun 2026
- Impairment of intangible assets excluding goodwill60 · Sep 2014 to Jun 2026
- Accumulated other comprehensive income loss net of tax59 · Dec 2014 to Jun 2026
- Amortization of intangible assets58 · Dec 2014 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest58 · Dec 2014 to Jun 2026
- Cost of goods and services sold (US GAAP)58 · Dec 2014 to Jun 2026
- Gross profit (US GAAP)58 · Dec 2014 to Jun 2026
- Income tax expense benefit58 · Dec 2014 to Jun 2026
- Interest expense (US GAAP)58 · Dec 2014 to Jun 2026
- Operating expenses (US GAAP)58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax58 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax58 · Dec 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans adjustment net of tax58 · Dec 2014 to Jun 2026
- Other nonoperating income expense58 · Dec 2014 to Jun 2026
- Profit loss58 · Dec 2014 to Jun 2026
- Research and development expense excluding acquired in process cost58 · Dec 2014 to Jun 2026
- Restructuring charges58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Royalty expense58 · Dec 2014 to Jun 2026
- Selling general and administrative expense58 · Dec 2014 to Jun 2026
- Cash used to net share settle employee equity awards56 · Dec 2014 to Jun 2026
- Depreciation56 · Dec 2014 to Dec 2025
Segment21 concepts · 1,719 facts · Dec 2014 to Jun 2026
- Revenue533 · Dec 2014 to Jun 2026
- MedSurg171 · Dec 2015 to Jun 2026
- Goodwill145 · Dec 2015 to Jun 2026
- Goodwill translation and purchase accounting adjustments130 · Dec 2016 to Jun 2026
- Goodwill acquired during period110 · Dec 2015 to Jun 2026
- Corporate Expenses including hedging activities101 · Dec 2014 to Sep 2024
- Revenue (excluding assessed tax)94 · Mar 2019 to Mar 2026
- Operating Income Allocated to Reportable Segments84 · Mar 2015 to Sep 2024
- Depreciation72 · Dec 2014 to Jun 2026
- Operating income loss70 · Dec 2014 to Sep 2024
- Operating Segments52 · Dec 2022 to Jun 2026
- Segment reporting other item amount28 · Dec 2022 to Jun 2026
- Goodwill impairment loss26 · Dec 2015 to Dec 2020
- Operating Income25 · Dec 2015 to Sep 2024
- Cardiac Rhythm Management21 · Dec 2015 to Dec 2017
- Total Assets21 · Dec 2015 to Dec 2019
- Goodwill period increase decrease13 · Mar 2018 to Dec 2018
- Goodwill purchase accounting adjustments12 · Dec 2015 to Dec 2016
- Goodwill written off related to sale of business unit6 · Dec 2019
- Goodwill transfers4 · Dec 2020
- Revenue from contracts with customers (excluding tax)1 · Sep 2019
Product7 concepts · 1,344 facts · Dec 2014 to Jun 2026
- Revenue1,302 · Dec 2016 to Jun 2026
- Cardiac Rhythm Management21 · Dec 2014 to Dec 2016
- MedSurg10 · Dec 2020 to Dec 2023
- Selling general and administrative expense6 · Dec 2016 to Dec 2021
- Operating income loss3 · Dec 2019 to Jun 2020
- Depreciation1 · Dec 2019
- Total Assets1 · Dec 2019
Geography4 concepts · 315 facts · Dec 2014 to Jun 2026
- Revenue231 · Dec 2016 to Jun 2026
- Revenue (excluding assessed tax)58 · Dec 2019 to Mar 2026
- Property, Plant & Equipment, Net14 · Dec 2015 to Dec 2019
- Other countries12 · Dec 2014 to Dec 2017
Guidance2 concepts · 184 facts · Feb 2021 to Jul 2026
- EPS (Diluted) Guidance92 · Feb 2021 to Jul 2026
- Revenue Growth Guidance92 · Feb 2021 to Jul 2026
Segments
3,378 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments30 members · 1,670 facts
- Cardiovascular387 · Dec 2014 to Jun 2026
- Medsurg385 · Dec 2014 to Jun 2026
- BSX Reportable Segments153 · Dec 2017 to Jun 2026
- Rhythmand Neuro115 · Dec 2016 to Dec 2021
- Bsxreportable segments94 · Mar 2019 to Mar 2026
- Cardiovascular61 · Jun 2015 to Jun 2026
- Medsurg61 · Jun 2015 to Jun 2026
- Rhythm Management59 · Dec 2014 to Dec 2017
- Special Charges47 · Dec 2014 to Sep 2024
- Specialty Pharmaceuticals36 · Sep 2019 to Sep 2022
- Corporate Expensesincludinghedgingactivities35 · Dec 2016 to Sep 2024
- Total Allocated To Reportable Segments34 · Dec 2014 to Sep 2024
- Total allocated to reportable segments30 · Dec 2015 to Sep 2024
- Rhythmand neuro23 · Dec 2017 to Dec 2021
- Corporate Expenses And Currency Exchange21 · Dec 2014 to Jun 2018
- Rhythm management15 · Dec 2015 to Jun 2018
- Cardiac Rhythm Management13 · Dec 2014 to Dec 2017
- Electrophysiology EP13 · Dec 2014 to Dec 2017
- Global Endoscopy Endo Reporting Unit13 · Dec 2014 to Dec 2017
- Global Interventional Cardiology Ic Reporting Unit13 · Dec 2014 to Dec 2017
- Global Neuromodulation Nm Reporting Unit13 · Dec 2014 to Dec 2017
- Global Peripheral Interventions Pi Reporting Unit13 · Dec 2014 to Dec 2017
- Global Urology Uro Reporting Unit13 · Dec 2014 to Dec 2017
- All Other Segments8 · Dec 2018 to Jun 2020
- Other6 · Dec 2020 to Dec 2022
- Specialty pharmaceuticals5 · Dec 2019 to Sep 2020
- Btgacquisition1 · Sep 2019
- BTG Acquisition1 · Sep 2019
- Excludes BTG Acquisition1 · Sep 2019
- All other segments1 · Dec 2019
Product or servicesrt:ProductOrServiceAxis18 members · 1,281 facts
- Cardiac Rhythm Management144 · Dec 2016 to Jun 2026
- Electrophysiology EP144 · Dec 2016 to Jun 2026
- Global Endoscopy Endo Reporting Unit144 · Dec 2016 to Jun 2026
- Global Neuromodulation Nm Reporting Unit144 · Dec 2016 to Jun 2026
- Global Urologyand Pelvic Health Reporting Unit144 · Dec 2016 to Jun 2026
- Global Peripheral Interventions Pi Reporting Unit132 · Dec 2016 to Sep 2025
- Watchman84 · Dec 2020 to Jun 2026
- Global Interventional Cardiology Ic Reporting Unit78 · Dec 2016 to Dec 2021
- Interventional Cardiology Therapies78 · Dec 2020 to Jun 2026
- Global Cardiology Reporting Unit72 · Dec 2020 to Sep 2025
- Specialty Pharmaceuticals56 · Sep 2019 to Sep 2022
- Other19 · Dec 2020 to Dec 2024
- Interventional Oncology And Embolization12 · Mar 2025 to Jun 2026
- Interventional Cardiology Vascular Therapies9 · Dec 2023 to Dec 2025
- Interventional Oncology Embolization9 · Dec 2023 to Dec 2025
- Shipping And Handling6 · Dec 2016 to Dec 2021
- BTG Spec Pharma5 · Dec 2019
- Btgspec pharma1 · Dec 2019
Statement geographicalsrt:StatementGeographicalAxis10 members · 277 facts
- Non Us48 · Dec 2016 to Jun 2026
- US48 · Dec 2016 to Jun 2026
- Emerging Markets46 · Dec 2016 to Dec 2025
- Asia Pacific24 · Dec 2016 to Dec 2025
- EMEA24 · Dec 2016 to Dec 2025
- Latin Americaand Canada24 · Dec 2016 to Dec 2025
- Emea20 · Dec 2019 to Mar 2026
- Latin americaand canada19 · Dec 2019 to Mar 2026
- Asia pacific19 · Dec 2019 to Mar 2026
- US Excluding Other Net Sales5 · Dec 2020 to Dec 2024
Product or serviceus-gaap:ProductOrServiceAxis8 members · 63 facts
- Cardiac Rhythm Management9 · Dec 2014 to Mar 2018
- Electrophysiology9 · Dec 2014 to Mar 2018
- Endoscopy9 · Dec 2014 to Mar 2018
- Interventional Cardiology9 · Dec 2014 to Mar 2018
- Neuromodulation9 · Dec 2014 to Mar 2018
- Peripheral Interventions9 · Dec 2014 to Mar 2018
- Urologyand Pelvic Health6 · Mar 2017 to Mar 2018
- Urology Womens Health3 · Dec 2014 to Dec 2016
Subsegments7 members · 49 facts
- Cardiac Rhythm Management7 · Mar 2015 to Mar 2017
- Electrophysiology EP7 · Mar 2015 to Mar 2017
- Global Endoscopy Endo Reporting Unit7 · Mar 2015 to Mar 2017
- Global Interventional Cardiology Ic Reporting Unit7 · Mar 2015 to Mar 2017
- Global Neuromodulation Nm Reporting Unit7 · Mar 2015 to Mar 2017
- Global Peripheral Interventions Pi Reporting Unit7 · Mar 2015 to Mar 2017
- Global Urology Uro Reporting Unit7 · Mar 2015 to Mar 2017
Statement geographicalus-gaap:StatementGeographicalAxis11 members · 38 facts
- US6 · Dec 2014 to Mar 2018
- Other countries5 · Dec 2015 to Dec 2019
- Us5 · Dec 2015 to Dec 2019
- Ie4 · Dec 2016 to Dec 2019
- JP4 · Dec 2014 to Dec 2017
- Other Countries4 · Dec 2014 to Dec 2017
- Asia Pacific2 · Mar 2017 to Mar 2018
- EMEA2 · Mar 2017 to Mar 2018
- Emerging Markets2 · Mar 2017 to Mar 2018
- Latin Americaand Canada2 · Mar 2017 to Mar 2018
- Non Us2 · Mar 2017 to Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary82 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary170 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes58 claims from 8 reports · Dec 2017 to Dec 2025
- Risk factors277 risks from 10 annual reports · 2016 to 2025
Earnings calls
30 calls · Apr 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
- FY2026 Q1Apr 22, 2026
- FY2025 Q4Feb 4, 2026
- FY2025 Q3Oct 22, 2025
- FY2025 Q2Jul 23, 2025
- FY2025 Q1Apr 23, 2025
- FY2024 Q4Feb 5, 2025
- FY2024 Q3Oct 23, 2024
- FY2024 Q2Jul 24, 2024
- FY2024 Q1Apr 24, 2024
- FY2023 Q4Jan 31, 2024
- FY2023 Q3Oct 26, 2023
- FY2023 Q2Jul 27, 2023
- FY2023 Q1Apr 26, 2023
- FY2022 Q4Feb 1, 2023
- FY2022 Q3Oct 26, 2022
Executive media
3 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Conference talks2 · Apr 2026 to Jun 2026
- Other appearances1 · Aug 2024
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.